SMARCB1 and neoplasm: The tumor mutation burden (TMB) was 1.1 mutations/Mb (Fig. 3). The NGS analysis included the investigation of important markers, such as MMR, MSI, PTEN, PIK3CA, TP53, beta-catenin, etc. Our NGS test report showed SMARCB1, CTNNBI, MMR, MSI, PTEN, PIK3CA, TP53 were negative.